A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 Lotion in Healthy Volunteers

Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 Lotion in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2014

At a glance

  • Drugs Omaveloxolone (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Ocular inflammation; Ocular pain; Skin disorders
  • Focus Adverse reactions
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 15 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Mar 2014 Planned number of patients changed from 22 to 32, as per ClinicalTrials.gov record.
    • 13 Mar 2014 Planned End Date changed from 1 Feb 2014 to 1 Apr 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top